comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 06:42:39 Page View：15

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： David Sabatini, ex
Next article： Walensky prepares to leave CDC — and Congress — behind

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Adam's Biotech Scorecard: Do Sarepta's exon

ThisistheonlineeditionofAdam’sBiotechScorecard,asubscriber-onlynewsletter.STAT+subscriberscansignuph

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Heat waves linked to early deliveries, preterm births in new study

RebeccaNoble/GettyImagesHeatwavesarebecomingmorefrequentandmoreintense,posingmoreofahealthriskaround

comprehensive

focus

explore

Heat waves linked to early deliveries, preterm births in new study